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Estonian concentrated HIV epidemic started in August
2000 when rare HIV-1 CRF06_cpx was introduced
into the population of intravenous drug users (IDUs).
The majority of these HIV-positive subjects are likely
co-infected with HCV but the prevalence of HCV and its
genotypes during HIV concentrated epidemic in Estonia is
largely unknown. The Estonian HIV database collects clin-
ical and laboratory data (including HCV) of HIV-positive
patients on medical care. Of 4500 patients on medical care
3500 are entered into Estonian HIV database (in total
8664 diagnosed).
Aim: to describe the prevalence of HCV infection
and the distribution of the HCV genotypes among
HIV-positive subjects infected during HIV concen-
trated epidemic in Estonia.
Data for present analyses was extracted from Estonian
HIV database on 2nd of January 2014 and it comprised
subjects diagnosed HIV-positive from 2000.
In total 2,420 of 3,476 (70%) HIV-positive subjects were
HCV antibody positive and 1,184 (64%) were HCV RNA
positive. More than half of HCV-positives were men (66%)
and the median age was 32 years (inter quartile range
30-36 y). The prevalence of HCV was higher in subjects
verified to be HIV-positive between 2002 and 2010 as
compared to between 2011 and 2013 (90% – 60% in
2002 – 2010 vs 50% – 45% in 2011 – 2013; p <0.05). The
prevalence of HCV-positivity was equally high in subjects
reporting the use of intravenous drugs (88%), the use of
other narcotics but intravenous drugs (69%) and persons
who have not reported the use of illegal drugs (71%). In
total 640 subjects had HCV genotype data available. The
dominating genotypes were Ib (53%) and IIIa (36%), how-
ever, in recent years the prevalence of genotype Ia is rais-
ing (from 2.6% in 2005 to 25% in 2013). The distribution
of HCV genotypes between different IDUs and non-IDUs
was similar. Altogether 5% of HCV RNA positive subjects
(66% with genotype Ib or IIIa; 29% with mixed or
unknown; 5% with Ia or II) received HCV treatment and
all except one admitted the drug usage. Of 59 subjects 48
(81%) received both HCV and HIV therapy.
Decreased prevalence of HCV-positive subjects among
HIV-positives may suggest a lowered HIV transmission
through intravenous route during the last years. The
high prevalence of HCV in persons who did not report
the use of illegal drugs might indicate under-reported
drug usage in this population.
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